10-K: Terns Pharmaceuticals Reports Full Year 2024 Results, Highlights Clinical Progress in Oncology and Obesity Programs

Terns Pharmaceuticals' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including TERN-701 for CML and TERN-601 for obesity.

Summary

• Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, filed its 10-K report for the fiscal year ended December 31, 2024.
• The company is focused on developing small-molecule product candidates for oncology and obesity.
• TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor for CML, is currently in a Phase 1 trial (CARDINAL) with additional data expected in Q4 2025.
• TERN-601, an oral GLP-1 receptor agonist for obesity, has initiated a Phase 2 trial (FALCON) with 12-week data expected in Q4 2025.
• TERN-501, a THRagonist, is being evaluated for opportunities in other metabolic diseases after limiting spend in MASH development.
• The company is also engaged in discovery efforts for TERN-800 series, GIPR modulators for obesity.
• The company had cash, cash equivalents, and marketable securities of approximately $358.2 million as of December 31, 2024, expected to fund operations into 2028.
• The net loss attributable to common stockholders for the years ended December 31, 2024 and 2023 was approximately $88.9 million and $90.2 million, respectively.
• The company relies on third-party manufacturers for drug supplies and has no long-term agreements with them.
• The company intends to establish a targeted commercial infrastructure in key geographies prior to regulatory approval of its drug therapies.

Sentiment

Score: 6

Explanation: The document presents a mix of positive clinical trial progress and financial stability, balanced by the inherent risks and challenges of a clinical-stage biopharmaceutical company.

Positives

• Positive early data from the Phase 1 trial of TERN-701.
• Phase 2 trial of TERN-601 initiated.
• TERN-601 demonstrated weight loss over 28 days up to 5.5% and favorable safety and tolerability despite rapid dose titration every three days.
• FDA granted Orphan Drug Designation for TERN-701.
• Existing capital resources are expected to fund planned operating expenses into 2028.

Negatives

• The company has a limited operating history and no products approved for commercial sale.
• The company has incurred significant losses since its inception and anticipates continuing to incur significant losses.
• The company relies completely on third parties to manufacture its clinical drug supplies and intends to rely on third parties to produce commercial supplies of any approved product candidate.
• The company has no long-term agreements with its current contract manufacturers.
• The company has no sales organization.

Risks

• The company will require substantial additional financing to achieve its goals.
• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of its product candidates.
• Clinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• The company faces significant competition for its drug discovery and development efforts.
• The company's development programs are focused on product candidates for the treatment of CML and obesity, and the outcome of clinical trials may not be favorable.
• The company relies on third parties to conduct, supervise, and monitor its preclinical and clinical trials.
• The successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies.
• The company's current and any future product candidates could be alleged to infringe patent rights and other intellectual property rights of third parties.
• Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact the company's business and operating results.
• China's economic, political, and social conditions, as well as government policies, could affect the company's ability to operate its business.

Future Outlook

The company expects its existing capital resources will fund its planned operating expenses into 2028 and plans to continue advancing its product candidates through clinical trials and pursue regulatory approval.

Industry Context

The report provides context on the competitive landscape in CML and obesity, noting companies with development programs in these areas and highlighting the increasing prevalence of obesity and the unmet need for safe, tolerable, and effective pharmacological interventions.

Comparison to Industry Standards

• The report compares TERN-701 to asciminib, the first approved allosteric TKI, noting opportunities to develop a best-in-class allosteric TKI with improved efficacy, safety, and convenience.
• The report compares TERN-601 to other oral GLP-1 receptor agonists under development, such as aleniglipron, orforglipron, and danuglipron, noting limitations of GLP-1 receptor agonists.

Management Changes

Stakeholder Impact

• Shareholders: Dilution possible from future equity offerings.
• Employees: Potential for career growth with company progress.
• Patients: Potential for new treatment options for CML and obesity.

Next Steps

• Initiate dose expansion in the CARDINAL trial in Q2 2025.
• Report additional safety and efficacy data from CARDINAL in Q4 2025.
• Report 12-week data from the Phase 2 FALCON trial of TERN-601 in Q4 2025.
• Nominate a GIPR antagonist development candidate based on in-house discoveries.

Key Dates

Keywords

TERN-701, TERN-601, TERN-501, CML, obesity, clinical trials, GLP-1 receptor agonist, THRagonist, GIPR modulators, biopharmaceutical, oncology, metabolic diseases